That compares to a loss of $1.8 million, or 6 cents per share, in the first quarter of 2009. First-quarter revenue dropped to $1.5 million from $20.9 million. Analysts expected a loss of 41 cents per share on nearly $6 million in revenue, according to a survey by Thomson Reuters. The company attributed part of its revenue decline to the end of a collaboration with Wyeth, which was purchased by Pfizer Inc. last year. Progenics also recorded a $15-million payment from Ono Pharmaceutical Co. Ltd. in the first quarter of 2009.